$AMAG News
Last published 3y ago
- 3y agoMGTXAMAGLandsdowne Labs Names Bryan Laulicht CEOBusiness WireCompany cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive
- 4y agoDVAXHARPPARIS:ALSENAMAGSensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent DirectorBusiness WireRegulatory News: Sensorion (PARIS:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the appointme
- 5y agoAMAGAspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension - NCT04908982ClinicalTrials.govPreterm Preeclampsia, Preeclampsia, Gestational Hypertension, (and 2 more...)
- 5y agoAMAGNew patent application published for: Apparatus and Method for SortingUS Patent Applications (USPTO)
- 5y agoAMAGAMAG Pharmaceuticals Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection)GlobeNewswireWALTHAM, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. has submitted its response to the FDA’s Notice of Opportunity for a Hearing (“NOOH”) regarding the Agency’s proposal to...
- 5y agoAMAGCovis Group Completes Acquisition of AMAG PharmaceuticalsPR NewswireCovis Group S.à r.l. ("Covis") today announced the completion of its acquisition of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) through the successful...
- 6y agoNTNCXOAMAGRESIMoore Kuehn Encourages NTN, CXO, AMAG, and RESI Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 6y agoAMAGAMAG Pharmaceuticals Requests Hearing to Maintain Makena® (Hydroxyprogesterone Caproate Injection) as a Treatment Option for Clinically Indicated Pregnant PatientsGlobeNewswireWALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Drug...
- 6y agoVRTUAMAGWPXGLIBAMoore Kuehn Encourages GLIBA, WPX, VRTU, and AMAG Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether...
- 6y agoAMAGAMAG Pharmaceuticals Provides Update on FDA’s Proposal Regarding Makena® (Hydroxyprogesterone Caproate Injection)GlobeNewswireThe product remains on the marketAMAG has 15 days to respond to the FDAAMAG continues to expect its recently announced tender offer and merger to close in November 2020 WALTHAM, Mass., Oct. 05, 2020...
- 6y agoAMAGCovis Group Announces Agreement to Acquire AMAG PharmaceuticalsGlobeNewswireAddition of AMAG’s category leading treatments positions Covis to become a global market leader of therapeutic solutions for life-threatening conditions and chronic illnesses Covis will commence a...
- 6y agoAMAGAMAG Pharmaceuticals to Participate in H.C. Wainwright 22nd Annual Global Investment ConferenceGlobeNewswireWALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Scott Myers, Chief Executive Officer, and Brian Piekos, Chief Financial Officer,...
- 6y agoAMAGAMAG Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswireFinancial guidance reissued to include EBITDA-positive projection for second-half 2020 Strategic shift and momentum build through recent business development activities Brian Piekos promoted to...
- 6y agoAMAGAMAG Pharmaceuticals to Host Second Quarter FY 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020GlobeNewswireWALTHAM, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its second quarter 2020 financial results will be released on Thursday, August 6,...
- 6y agoAMAGAMAG Pharmaceuticals Completes Divestment of Women’s Health AssetsGlobeNewswireVyleesi® returned to Palatin Technologies Company focuses on optimizing marketed assets and development of its innovative pipeline WALTHAM, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- AMAG...
- 6y agoAMAGAMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New ZealandGlobeNewswireAgreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties ...
- 6y agoAMAGAMAG Announces Presentation of Ciraparantag Data at the International Society on Thrombosis and HaemostasisGlobeNewswireWALTHAM, Mass., July 12, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the poster presentation of data from two Phase 2 randomized, placebo-controlled, dose...
- 6y agoAMAGAMAG Pharmaceuticals Completes Sale of its Rights to Intrarosa® to Millicent Pharma for up to $125 MillionGlobeNewswireTransaction allows AMAG to advance its strategic focus on Feraheme, Makena and its pipeline, consistent with previously announced plans Millicent Pharma uniquely positioned to drive revenue growth of...
- 6y agoAMAGAMAG Pharmaceuticals, Inc. (AMAG) CEO Scott Myers on Q1 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
- 6y agoAMAGAMAG Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswireFeraheme® (ferumoxytol injection) posts strong first quarter results Company implements a workforce reduction of approximately 30 percent or 140 positions, as part of a planned decrease in operating...
- 6y agoAMAGAMAG Pharmaceuticals to Host First Quarter 2020 Financial Results Conference Call and Webcast on Monday, May 11, 2020GlobeNewswireWALTHAM, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its first quarter 2020 financial results will be released on Monday, May 11, 2020...
- 6y agoAMAGAMAG Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateGlobeNewswireWALTHAM, Mass., March 04, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended...
- 6y agoAMAGAMAG Pharmaceuticals Announces Changes to Medical Development OrganizationGlobeNewswireWALTHAM, Mass., March 04, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced changes to its medical development organization. Effective March 31, 2020, Julie Krop,...
- 6y agoAMAGAMAG Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will participate in the following investor conferences: SVB Leerink 9th...
- 6y agoAMAGAMAG Pharmaceuticals Announces Leadership Transition, Results of Strategic Review to Unlock Shareholder Value and Financial UpdateGlobeNewswireInitiating CEO transition plan Divesting Intrarosa® and Vyleesi® 2020 financial guidance reflects reduction in annual operating expenses of more than $100M and a return to positive adjusted EBITDA ...
- 6y agoAMAGAMAG Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Jan. 03, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will present at the 38th Annual J.P. Morgan Healthcare Conference on...
- 6y agoAMAGAMAG Pharmaceuticals Awards Four Grants to Support Preterm Birth and Preeclampsia ResearchGlobeNewswireWALTHAM, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- As part of the company’s ongoing support of research to reduce preterm birth and preeclampsia and associated complications, AMAG Pharmaceuticals,...
- 7y agoAMAGAMAG Pharmaceuticals Announces Third Quarter 2019 Financial Results and Provides Corporate UpdateGlobeNewswireCommercial products achieve strong revenue and market share performance Vyleesi™ (bremelanotide injection) launched nationally in September Committed to work with the FDA to keep Makena available...
- 7y agoAMAGAMAG Reports on FDA Advisory Committee Meeting for Makena® (Hydroxyprogesterone Caproate Injection)GlobeNewswireWALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the U.S. Food and Drug Administration’s (FDA) Bone, Reproductive and Urologic Drugs...
- 7y agoAMAGAMAG Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss the Results of the Makena PROLONG TrialGlobeNewswireWALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug...
- 7y agoAMAGAMAG Pharmaceuticals Announces the Publication of the PROLONG Trial Evaluating 17-OHPC in the American Journal of PerinatologyGlobeNewswireWALTHAM, Mass., Oct. 25, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the results of PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) were...
- 7y agoAMAGAMAG Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Friday, November 1, 2019 at 8:00 a.m. ETGlobeNewswireWALTHAM, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its third quarter 2019 financial results will be released on Friday, November 1, 2019...
- 7y agoAMAGAMAG Pharmaceuticals Announces the Publication of the Phase 3 Vyleesi™ (Bremelanotide Injection) Data in Obstetrics & GynecologyGlobeNewswireWALTHAM, Mass., Oct. 11, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced that the data from its two pivotal, double-blind placebo-controlled Phase 3 trials (RECONNECT)...
- 7y agoAMAGAMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LPGlobeNewswireWALTHAM, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) (“AMAG”) today announced that it has entered into a settlement agreement with Caligan Partners LP...
- 7y agoAMAGAMAG Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will participate in the Cantor Fitzgerald Global Healthcare Conference in New York on Thursday, October 3,...
- 7y agoAMAGAMAG Pharmaceuticals to Present at Morgan Stanley Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will participate in the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2019. Bill...
- 7y agoAMAGAMAG Urges Stockholders to Take No Action on Caligan Partners’ Consent Solicitation MaterialsGlobeNewswireWALTHAM, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) (“AMAG” or the “Company”) today responded to the preliminary consent solicitation filed by Caligan...
- 7y agoAMAGAMAG Pharmaceuticals, Inc. (AMAG) CEO William Heiden on Acquisition of Perosphere Pharmaceuticals (Transcript)Earnings Call Transcripts
- 8y agoAMAGAMAG Pharmaceuticals, Inc. (AMAG) CEO William Heiden on Q3 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoAMAGAMAG Pharmaceuticals, Inc. (AMAG) CEO Bill Heiden on Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoAMAGAMAG Pharmaceuticals' (AMAG) CEO William Heiden Presents at Deutsche Bank 41st Annual Health Care Conference (Transcript)Earnings Call Transcripts
- 10y agoAMAGAMAG Pharmaceuticals' (AMAG) CEO Bill Heiden on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoAMAGAMAG Pharmaceuticals (AMAG) Q4 2015 Results - Earnings Call WebcastEarnings Call Transcripts
- 13y agoAMAGAMAG Pharmaceuticals to Present at the Needham Healthcare ConferenceBusiness WireLEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, AMAG’s chief executive officer, will present at the Needham Healthcare Conference on Wednesday, May 1, 2013 at 12:50 p.m. Eastern time. The presentation will include a company overview and business update.
- 13y agoAMAGAMAG Announces First Quarter 2013 Financial ResultsBusiness WireLEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a specialty pharmaceutical company, today reported unaudited consolidated financial results for the quarter ended March 31, 2013. Total revenues for the first quarter of 2013 were $17.9 million, 16 percent greater than the first quarter of 2012, driven by increased Feraheme® (ferumoxytol) U.S. sales. As of March 31, 2013 ...
- 13y agoAMAGAMAG Pharmaceuticals, Inc. to Host Conference Call on April 23, 2013 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2013Business WireLEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2013 after the U.S. financial markets close on Tuesday, April 23, 2013. The announcement will be followed by a conference call and webcast with slides at 4:30 p.m. ET during which management will provide a business upda ...
- 13y agoAMAGAMAG Pharmaceuticals Announces Positive Preliminary Results from an Extension Study Evaluating the Safety and Efficacy of Repeat Dosing with Ferumoxytol in Patients with Persistent or Recurring Iron Deficiency Anemia, Regardless of the Underlying CauseBusiness WireLEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced positive preliminary data from the IDA-303 study. IDA-303 is a single arm, open-label extension study that evaluated the safety and efficacy of repeat dosing with ferumoxytol in patients with persistent or recurring iron deficiency anemia (IDA) regardless of the underlying cause and a history of unsatisfac ...
- 13y agoAMAGAMAG Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Feraheme Label Expansion to Include Iron Deficiency Anemia Patients Who Cannot Take Oral IronBusiness WireLEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that the United States Food and Drug Administration (FDA) has accepted for review the company’s supplemental new drug application (sNDA) for Feraheme® (ferumoxytol) Injection for Intravenous (IV) use, which was submitted to the FDA in December 2012. The sNDA requests FDA approval to expand the indication f ...
- 13y agoAMAGAMAG Announces Fourth Quarter and Year End 2012 Financial ResultsBusiness WireLEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a specialty pharmaceutical company, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2012. Total revenues for 2012 were 39% greater than 2011, driven by the recognition of milestone payments received from Takeda Pharmaceutical Company Limited, the company’s ex-US ...
- 13y agoAMAGAMAG Pharmaceuticals, Inc. to Present at Upcoming Healthcare ConferencesBusiness WireLEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, AMAG’s chief executive officer, will participate in the RBC Capital Markets Global Healthcare Conference on Tuesday, February 26, 2013 at 9:30 am ET in New York and the Cowen and Company 33rd Annual Healthcare Conference on Monday, March 4, 2013 at 2:50 pm ET in Boston. The presentatio ...